TherapeuticsMD (TXMD) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Noble Financial Lifts PT on TherapeuticsMD (TXMD) to $15; Sees Reduced TX 12-001HR Risk
March 11, 2015 11:47 AM EDTNoble Financial affirms TherapeuticsMD, Inc. (AMEX: TXMD) at Buy and nudges its price target from $14 up to $15 following Q4 results and update issued after markets closed Tuesday.
Analyst Nathan Cali noted that the bump higher in TXMD's price target stems from an increased cash balance, lowering the cost of capital by 5 points to 15 percent, and increasing risk-adjusted rNPV for TX 12-001HR, bioidentical estradiol/progesterone.
Cali also noted the following key points from the quarter and recent updates:
March 10th, 2015 reported relatively inline full year 2015 financial... More